|
À̳ë¼Ä¡ |
À¯¸Á¹ÙÀÌ¿À ÀÓ»óÆÀÀå,µð·ºÅÍ PM RA QA »ç¾÷°³¹ßBD
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
¼ö½Ãä¿ë |
3³â¡è |
ä¿ë½Ã |
04.02 |
|
|
ÇdzÊŬ½áÄ¡ |
¸é¿ªÇ×ü ¿¬±¸°³¹ß Â÷Àå±Þ - ¹ÙÀÌ¿À ±â¾÷
¼¿ï °³²±¸ | ´ëÇпø(¼®»ç) Á¹¾÷ |
¿¬±¸/¿¬±¸±âȹ |
8³â¡è |
ä¿ë½Ã |
01.08 |
|
|
À̳ë¼Ä¡ |
2019 ÇϹݱâ ÇìµåÇåÅ͸ðÁý(½ÅÀÔ, °æ·Â)
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
ÇìµåÇåÅÍ |
°æ·Â¹«°ü |
ä¿ë½Ã |
09.27 |
|
|
À¯ÇÑȸ»ç ÀÎÅÚ¸®Àü½ºÄÚ¸®¾Æ |
[±Û·Î¹ú Á¦¾à»ç] RA ¸ðÁý (½ÅÀÔ°¡´É)
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
¾à»ç/ÇѾà»ç |
°æ·Â¹«°ü |
ä¿ë½Ã |
09.27 |
|
|
À̳ë¼Ä¡ |
±Û·¯¹ú cro µð·ºÅÍ Æ÷Áö¼Ç (Á¦Åð¡´É)
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
ÀÓ»ó BD/RA/QA |
10³â¡è |
ä¿ë½Ã |
05.29 |
|
|
À̳ë¼Ä¡ |
ÀÇ·á±â±â ȸ»ç Global ÇØ¿Ü RA open
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
ÀÓ»ó BD/RA/QA |
4³â¡è |
ä¿ë½Ã |
05.26 |
|
|
À̳ë¼Ä¡ |
±Û·Î¹ú CRO CRAÆ÷Áö¼Ç
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
4³â¡è |
ä¿ë½Ã |
05.26 |
|
|
(ÁÖ)ÇÇÇÃÄɾî½áÄ¡ |
Marketing Manager(Medical device/pharmaceutical Indu.)
¼¿ï °³²±¸ | Çз¹«°ü |
¸¶ÄÉÆÃ/±âȹ/±³À° |
5³â¡è |
ä¿ë½Ã |
05.21 |
|
|
À̳ë¼Ä¡ |
ÇìµåÇåÅÍ Ãʺù
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
ÇìµåÇåÅÍ |
°æ·Â¹«°ü |
ä¿ë½Ã |
05.19 |
|
|
Ä¿¸®¾îÆ÷Ä¿½º |
Çã°¡ RA ä¿ë
¼¿ï °³²±¸ | ´ëÇÐ(4³â) ÀçÇÐ |
¶óÀ̼¾½ºIn/Out |
5³â¡è |
ä¿ë½Ã |
03.14 |
|
|
Çì´Ï¾Ø¸ÓÄÚÀÌ |
Pharmacovigilance (MI) Specialist / Regulatory Affairs
¼¿ï °³²±¸, ¼¿ï ¼ÛÆı¸ | ´ëÇпø(¼®»ç) Á¹¾÷ |
¾à»ç/ÇѾà»ç |
5³â¡è |
ä¿ë½Ã |
03.14 |
|
|
ÄÚ¸®¾Æºê·¹ÀÎ ((ÁÖ)¿¡ÀÌÄ¡¾ËÇãºê) |
[À¯¸í¿Ü±¹°è] ¾È°ú MR
¼¿ï °³²±¸ | Çз¹«°ü |
Á¦¾à¿µ¾÷/ÀÇ·á±â¿µ¾÷ |
2³â¡è |
ä¿ë½Ã |
02.14 |
|
|
Çì´Ï¾Ø¸ÓÄÚÀÌ |
RA (1³â °è¾àÁ÷)
¼¿ï °³²±¸, ¼¿ï ¼ÛÆı¸ | ´ëÇÐ(4³â) Á¹¾÷ |
¾à»ç/ÇѾà»ç |
3³â¡è |
ä¿ë½Ã |
11.14 |
|
|
³ª¿ìÆÊÄÁ¼³Æà |
»óÀåÁß°ß±â¾÷ °³¹ßº»ºÎÀå ¸ðÁý
¼¿ï °³²±¸ | Çз¹«°ü |
¼ö½Ãä¿ë |
°æ·Â¹«°ü |
ä¿ë½Ã |
10.11 |
|
|
³ª¿ìÆÊÄÁ¼³Æà |
·ÎÄà ÀÓ»ó CRO»ç ÀÓ»ó BD °æ·ÂÀÚ Ã¤¿ë
¼¿ï °³²±¸ | Çз¹«°ü |
¼ö½Ãä¿ë |
°æ·Â¹«°ü |
ä¿ë½Ã |
10.11 |
|